Diego Casas Deza , Ana Belén Julián Gomara , Eva Caudevilla Biota , Belén Beltrán , Eugeni Domènech , Ana Gutiérrez Casbas , Miriam Mañosa , Yamile Zabana , Lourdes Roc Alfaro , Emilio Valverde Romero , Elena García González , Beatriz Sicilia , Viviana Laredo , Maria José Alcalá Escriche , Lucia Madero Velázquez , Rocío Ferreiro-Iglesias , Antonia Palmero Pérez , Margalida Calafat , Saioa Rubio Iturria , Irene Moraleja Yudego , Santiago García-López
{"title":"加强剂量的 SARS-COV-2 疫苗可提高炎症性肠病患者的血清转换率。GETECCU前瞻性多中心研究（VACOVEII研究）的结果","authors":"Diego Casas Deza , Ana Belén Julián Gomara , Eva Caudevilla Biota , Belén Beltrán , Eugeni Domènech , Ana Gutiérrez Casbas , Miriam Mañosa , Yamile Zabana , Lourdes Roc Alfaro , Emilio Valverde Romero , Elena García González , Beatriz Sicilia , Viviana Laredo , Maria José Alcalá Escriche , Lucia Madero Velázquez , Rocío Ferreiro-Iglesias , Antonia Palmero Pérez , Margalida Calafat , Saioa Rubio Iturria , Irene Moraleja Yudego , Santiago García-López","doi":"10.1016/j.gastre.2024.04.041","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The response to SARS-CoV-2 vaccination decreases in inflammatory bowel disease (IBD) patients, specially under anti-TNF treatment. However, data on medium-term effectiveness are limited, specially using new recommended seroconversion rate (>260<!--> <!-->BAU/mL). Our aim was to evaluate the 6-month<!--> <!-->><!--> <!-->260 BAU-seroconversion rate after full vaccination and after booster-dose.</div></div><div><h3>Methods</h3><div>VACOVEII is a Spanish multicenter, prospective study promoted by GETECCU. IBD patients full vaccinated against SARS-CoV-2 and without previous COVID-19 infection, treated or not with immunosuppressants, were included. The booster dose was administered 6 months after the full vaccination. Seroconversion was set at 260<!--> <!-->BAU/mL, according to most recent recommendations and was assessed 6 months after the full vaccination and 6 months after booster-dose.</div></div><div><h3>Results</h3><div>Between October 2021 and March 2022, 313 patients were included (124 no treatment or mesalazine; 55 immunomodulators; 87 anti-TNF; 19 anti-integrin; and 28 ustekinumab). Most patients received mRNA-vaccines (86%). Six months after full vaccination, overall seroconversion rate was 44.1%, being significantly lower among patients on anti-TNF (19.5%, <em>p</em> <!--><<!--> <!-->0.001) and ustekinumab (35.7%, <em>p</em> <!-->=<!--> <!-->0.031). The seroconversion rate after booster was 92%. Again, anti-TNF patients had a significantly lower seroconversion rate (67%, <em>p</em> <!--><<!--> <!-->0.001). mRNA-vaccine improved seroconversion rate (OR 11.720 [95% CI 2.26–60.512]).</div></div><div><h3>Conclusion</h3><div>The full vaccination regimen achieves suboptimal response in IBD patients, specially among those anti-TNF or ustekinumab. The booster dose improves seroconversion rate in all patients, although it remains limited in those treated with anti-TNF. These results reinforce the need to prioritize future booster doses in patients on immunosuppressants therapy, specially under anti-TNF, and using mRNA-vaccines.</div></div>","PeriodicalId":100569,"journal":{"name":"Gastroenterología y Hepatología (English Edition)","volume":"47 8","pages":"Pages 821-833"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A booster dose of SARS-COV-2 vaccine improves suboptimal seroconversion rates in patients with inflammatory bowel disease. Results of a prospective multicenter study of GETECCU (VACOVEII study)\",\"authors\":\"Diego Casas Deza , Ana Belén Julián Gomara , Eva Caudevilla Biota , Belén Beltrán , Eugeni Domènech , Ana Gutiérrez Casbas , Miriam Mañosa , Yamile Zabana , Lourdes Roc Alfaro , Emilio Valverde Romero , Elena García González , Beatriz Sicilia , Viviana Laredo , Maria José Alcalá Escriche , Lucia Madero Velázquez , Rocío Ferreiro-Iglesias , Antonia Palmero Pérez , Margalida Calafat , Saioa Rubio Iturria , Irene Moraleja Yudego , Santiago García-López\",\"doi\":\"10.1016/j.gastre.2024.04.041\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>The response to SARS-CoV-2 vaccination decreases in inflammatory bowel disease (IBD) patients, specially under anti-TNF treatment. However, data on medium-term effectiveness are limited, specially using new recommended seroconversion rate (>260<!--> <!-->BAU/mL). Our aim was to evaluate the 6-month<!--> <!-->><!--> <!-->260 BAU-seroconversion rate after full vaccination and after booster-dose.</div></div><div><h3>Methods</h3><div>VACOVEII is a Spanish multicenter, prospective study promoted by GETECCU. IBD patients full vaccinated against SARS-CoV-2 and without previous COVID-19 infection, treated or not with immunosuppressants, were included. The booster dose was administered 6 months after the full vaccination. Seroconversion was set at 260<!--> <!-->BAU/mL, according to most recent recommendations and was assessed 6 months after the full vaccination and 6 months after booster-dose.</div></div><div><h3>Results</h3><div>Between October 2021 and March 2022, 313 patients were included (124 no treatment or mesalazine; 55 immunomodulators; 87 anti-TNF; 19 anti-integrin; and 28 ustekinumab). Most patients received mRNA-vaccines (86%). Six months after full vaccination, overall seroconversion rate was 44.1%, being significantly lower among patients on anti-TNF (19.5%, <em>p</em> <!--><<!--> <!-->0.001) and ustekinumab (35.7%, <em>p</em> <!-->=<!--> <!-->0.031). The seroconversion rate after booster was 92%. Again, anti-TNF patients had a significantly lower seroconversion rate (67%, <em>p</em> <!--><<!--> <!-->0.001). mRNA-vaccine improved seroconversion rate (OR 11.720 [95% CI 2.26–60.512]).</div></div><div><h3>Conclusion</h3><div>The full vaccination regimen achieves suboptimal response in IBD patients, specially among those anti-TNF or ustekinumab. The booster dose improves seroconversion rate in all patients, although it remains limited in those treated with anti-TNF. These results reinforce the need to prioritize future booster doses in patients on immunosuppressants therapy, specially under anti-TNF, and using mRNA-vaccines.</div></div>\",\"PeriodicalId\":100569,\"journal\":{\"name\":\"Gastroenterología y Hepatología (English Edition)\",\"volume\":\"47 8\",\"pages\":\"Pages 821-833\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Gastroenterología y Hepatología (English Edition)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2444382424001135\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastroenterología y Hepatología (English Edition)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2444382424001135","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A booster dose of SARS-COV-2 vaccine improves suboptimal seroconversion rates in patients with inflammatory bowel disease. Results of a prospective multicenter study of GETECCU (VACOVEII study)
Background
The response to SARS-CoV-2 vaccination decreases in inflammatory bowel disease (IBD) patients, specially under anti-TNF treatment. However, data on medium-term effectiveness are limited, specially using new recommended seroconversion rate (>260 BAU/mL). Our aim was to evaluate the 6-month > 260 BAU-seroconversion rate after full vaccination and after booster-dose.
Methods
VACOVEII is a Spanish multicenter, prospective study promoted by GETECCU. IBD patients full vaccinated against SARS-CoV-2 and without previous COVID-19 infection, treated or not with immunosuppressants, were included. The booster dose was administered 6 months after the full vaccination. Seroconversion was set at 260 BAU/mL, according to most recent recommendations and was assessed 6 months after the full vaccination and 6 months after booster-dose.
Results
Between October 2021 and March 2022, 313 patients were included (124 no treatment or mesalazine; 55 immunomodulators; 87 anti-TNF; 19 anti-integrin; and 28 ustekinumab). Most patients received mRNA-vaccines (86%). Six months after full vaccination, overall seroconversion rate was 44.1%, being significantly lower among patients on anti-TNF (19.5%, p < 0.001) and ustekinumab (35.7%, p = 0.031). The seroconversion rate after booster was 92%. Again, anti-TNF patients had a significantly lower seroconversion rate (67%, p < 0.001). mRNA-vaccine improved seroconversion rate (OR 11.720 [95% CI 2.26–60.512]).
Conclusion
The full vaccination regimen achieves suboptimal response in IBD patients, specially among those anti-TNF or ustekinumab. The booster dose improves seroconversion rate in all patients, although it remains limited in those treated with anti-TNF. These results reinforce the need to prioritize future booster doses in patients on immunosuppressants therapy, specially under anti-TNF, and using mRNA-vaccines.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
